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Drug discovery strategies based on natural products and traditional medicines are re-emerging as
attractive options.We suggest that drug discovery and development need not always be confined to new
molecular entities. Rationally designed, carefully standardized, synergistic traditional herbal
formulations and botanical drug products with robust scientific evidence can also be alternatives. A
reverse pharmacology approach, inspired by traditional medicine and Ayurveda, can offer a smart
strategy for new drug candidates to facilitate discovery process and also for the development of rational
synergistic botanical formulations.
Drug discovery scenario
Drug discovery is no longer a game of chance or just limited to the
availability of new technology. Better understanding of various
approaches and key learning from the past with the appropriate
strategy for the future is essential tomakea significantdifference [1].
During the past few years a large number of approved new drug
applications have originated from the biotechnology industry and
analysts expect a continuation of pharmaceutical-biotechnology
alliances to help expand pipelines [2]. Similarly, natural products
have contributed nearly half of all small molecules approved in
this decade. It has been suggested that the current drug discovery
approach of finding ‘new entity drugs’, if shifted to ‘combining
existing agents’ may be helpful. Therefore natural product drug
discovery based on ethnopharmacology and traditional medicines
may also be considered as attractive strategic options [3].
Seeking innovative paradigms
The age of the blockbuster drugs seem to have become a distant
dream [4]. For instance, in 2008only 21newmolecular entitieswere
approved byUSFDAand so few are anticipated to becomeblockbus-
ters. The usual distinctions drawn between breakthrough and me-
too drugsmay not be very relevant today [5]. Despite very stringent
and demanding regulatory processes, postapproval or postmarket-
ingwithdrawal ofnewdrugs continues. It is argued that the safetyof
newagents cannot be knownwith certainty until a drughas been in
themarket formanyyears [6]. Thishas led toa re-examinationof the
process of drug regulation and increased concern that the current
process is inadequate for the protection of public health [7]. The
United States Food and Drug Administration (US FDA)’s Drug
Watch and Drug Advisory Committee briefings on the new antic-
oagulant Ximelagatran from AstraZeneca, the Cox II inhibitor,
Vioxx from Merck and the case of the cancer vaccine Provenge
approval of Dendreon are typically indicative [8,9].
Societal expectations about drug safety and efficacy are rising
while R&D productivity in the pharmaceutical industry is falling.
The Critical Path Initiative of FDAwas intended tomodernize drug
development by incorporating recent scientific advances, shows a
proactive policy approach to enhance innovation opportunities in
a public/private partnership model [10]. We suggest that tradi-
tional medicine may offer better routes to the discovery, devel-
opment and delivery of new drugs with enhanced performance in
terms of cost, safety and efficacy. To this end, we believe that the
basic principles, experiential wisdom, holistic approach and sys-
tematic database of Ayurveda (Box 1 and Fig. 1) may offer useful
bioprospecting tools and an efficient discovery engine [11].
Rediscovering history
The history of medicine reveals that most of the early discoveries
resulted from either serendipity or folklore approaches, often
involving poisonous sources and not really from traditional
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medicines. The mass screening of plants in the search for new
leads or drugs is vastly expensive and inefficient. Yet, traditional
knowledge based bioprospecting offered better leads for the treat-
ment of AIDS and cancer. It is estimated that over 100 newnatural
product-based leads are in clinical development [12]. About 60%
of anticancer and 75%of anti-infective drugs approved from1981
to 2002 could be traced tonatural origins [13]. Amultidisciplinary
approach combining natural product diversity with total, com-
binatorial synthetic andbiosynthesismay provide an apt solution
to the current innovation quandary [14].
Combinatorial chemistry approaches based on natural products
from traditional medicine are being used to create screening
libraries that closely resemble drug-like compounds [15]. Since
most of these compounds are part of routinely used traditional
medicines, their tolerance and safety are relatively better known
than other synthetic chemical entities entering first-in-human
studies [16]. For instance, Piramal Life Sciences Ltd., Mumbai
has a unique and diverse library of over 5600 natural product
extracts from Indian medicinal plants inherited from the Hoechst
Research Center. Their first lead, NPB-001-05, has demonstrated
efficacy in various cellular and animal models, and is currently
undergoing human clinical trials for chronic myeloid leukemia.
The second lead, NPS31807, is being developed for the treatment
of chronic inflammatory disorders including rheumatoid arthritis.
The third lead, NPH30907, has been developed as a topical for-
mulation with good antidermatophyte activity against a panel of
microorganisms [17]. Thus, similar to microbiological sources,
traditional medicine-based bioprospecting may offer promising
new leads with compounds generally recognized as safe [18].
A large number of promising lead molecules that have come out
of Ayurveda includeRauwolfia alkaloids for hypertension, Psoralens
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BOX 1
Ayurveda – the knowledge of life
 Ayurveda is one of the oldest still extant, health traditions in the
world. Originating in India Ayurveda is based on Sankhya philosophy,
which means ‘rational enquiry into the nature of the truth’. Sanskrit
meaning of Ayu is life and Veda is knowledge or science.
 Charak Samhita (1000 BC) and Sushrut Samhita (100 AD) are the main
classics. Ayurveda materia medica give detailed descriptions of over
1500 herbs and 10,000 formulations. Madhav Nidan (800 AD) a
diagnostic classic provides over 5000 signs and symptoms.
 Life in Ayurveda is conceived as the union of body, senses, mind and
soul. The concept of Prakriti or human constitution plays a central
role in understanding health and disease in Ayurveda, which is
similar to modern pharmacogenomics.
 With over 400,000 registered Ayurveda practitioners, Government of
India Department of AYUSH (Ayurveda, Yoga, Unani, Siddha and
Homeopathy) has responsibility to regulate quality, education and
practice.
FIGURE 1
Ayurveda: overview of basic principles and therapeutics.
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for vitiligo, Holarrhena alkaloids for amoebiasis, guggulsterons as
hypolipidemic agents, Mucuna pruriens for Parkinson’s disease,
piperidines as bioavailability enhancers, baccosides for mental
retention, picrosides for hepatic protection, phyllanthins as anti-
virals, curcumines for inflammation, withanolides andmany other
steroidal lactones and glycosides as immunomodulators [19].
There is growing evidence to show that old molecules are
finding new applications through a better understanding of tradi-
tional knowledge and clinical observations. For instance, forskolin
has been revisited as adenylate cyclase activator, to treat condi-
tions including obesity and atherosclerosis [20]. Similarly, anti-
microbial berberine alkaloids are being investigated in
dyslipidemia with a mechanism different from statins [21].
Reverse pharmacology
The traditional knowledge-inspired reverse pharmacology
described here relates to reversing the routine ‘laboratory-to-clinic’
progress to ‘clinics-to-laboratories’ [22]. Earlier, the term reverse
pharmacology has been used in relation to ligand-independent
orphan functions that canmodulate well-defined drug targets, but
this review does not cover such aspects [23]. Reverse pharmacology
is defined here as a rigorous scientific approach of integrating
documented clinical experiences and experiential observations
into leads by transdisciplinary exploratory studies and further
developing these into drug candidates or formulations through
robust preclinical and clinical research [24]. In this process ‘safety’
remains the most important starting point and the efficacy
becomes a matter of validation. The novelty of this approach is
the combination of living traditional knowledge such as Ayurveda
and the application of modern technology and processes to pro-
vide better and safer leads.
Sir RamNath Chopra and Gananath Sen laid the foundation of
reverse pharmacology of medicinal plants by pursuing the clini-
cally documented effects of Ayurvedic drugs [25]. Rauwolfia
serpentina Benth, was a major discovery via this approach. Sen
and Bose were able to convincingly demonstrate the antihyper-
tensive and tranquillizing effects of the plant and also observed
unique side effects such as depression, extra pyramidal syn-
dromes, gynecomastia among others [26]. This effort led to a
watershed for new antidepressants, anti-Parkinson’s drugs and
prolactin-reducing drugs [27]. Reserpine is an example of an
antihypertensive alkaloid from Rauwolfia that became available
from such an approach.
Some promising work was undertaken almost two to three
decades ago through a joint drug research program between the
Indian Council of Medical Research (ICMR) and the Council for
Scientific and Industrial Research (CSIR) of the Government of
India. The cholesterol-lowering drug, Guggulipid, was developed
from Commiphora mukul, taking the lead from Ayurveda [28]. The
Drug Controller General of India (DCGI) approved this drug for
marketing in 1986. Guggulipid is being manufactured and mar-
keted by Cipla Pharmaceuticals Limited, but the limited availabil-
ity of authentic raw material has remained a limiting factor for its
widespread use. A memory enhancer developed from Bacopa mon-
nieri by the Central Drug Research Institute, Lucknow is also
licensed and marketed. Regrettably, the great potential of such
approaches has not been fully explored to create globally compe-
titive products.
In an attempt to pull industry and academia together to explore
the potential of herbal drug development, CSIR, under the
national network project known as NewMillennium Indian Tech-
nology Leadership Initiative (NMITLI), has instigated drug devel-
opment projects on psoriasis, osteoarthritis, hepatitis and diabetes
[29]. To this end, the ICMR has recently established an Advanced
Center of Reverse Pharmacology with initial focus on malaria,
sarcopenia and cognitive decline. We present here a few case
studies where a reverse pharmacology approach has been used
to expedite the drug development process.
Psoriasis
Psoriasis is one of the most common dermatological diseases,
affecting approximately 2% of the world population with no
preventive or curative therapy. Under the NMITLI project, Lupin
Limited in India undertook the development of a single plant-
based oral formulation adopting a reverse pharmacology approach
[30]. The botanical drug product (Desoris) is an extract of a single
plant that effectively modulates cellular function, leading to an
improvement in psoriatic lesions [31]. Extensive studies led to the
filing of an Investigational New Drug (IND) application in India.
This product has been developed to conform to FDA guidelines for
botanical drug products and DCGI norms on new drug develop-
ment. Currently, this product is undergoing Phase 3 clinical trials
across different centers in India.
Vaccine adjuvant
Despite centuries of vaccine use, still alum salts remain universal
vaccine adjuvants licensed for human use. They have limitations,
however, in engaging cellular immunity. Various immunostimu-
lants from natural and synthetic origin are being studied either to
replace or complement alum salts in vaccine formulations [32]. A
project to develop herbal vaccine adjuvants using a reverse phar-
macology approach based on Ayurveda and other studies [33,34]
has been supported by the Department of Science and Technology
(DST) of India and was undertaken by the Interdisciplinary School
of Health Sciences, University of Pune with the Serum Institute of
India as an industrial partner. The project used flow cytometry to
monitor the effects of fractions on antigen-specific protective
immunity and test materials were screened using in vivo potency
assays for pertussis or diphtheria. These models are routinely used
in potency testing of vaccines [35,36]. Within three years, this
project identified several semi-pure leads with considerable effi-
cacy with respect to polysaccharide, toxoid and recombinant
groups of vaccines. Further, these leads were found to modulate
T-helper cell immunity, which is crucial for efficient cellular and
humoral immunity. A detailed safety profile of one of the leads has
been established, which is found to be over 20 times more potent
than its effective preclinical immunomodulatory dose.
Traditional herbal formulations
Wesuggest that drug discoveryneednot be always confined to the
discovery of a single molecule. Many analysts believe that
the current ‘one drug fits all’ approach may be unsustainable in
the future. The growing interest in polypill concept is indicative
of the need to collectively address multiple targets, risk factors
or symptoms [37]. In the management of polygenic syndromes
and conditions there is renewed interest in multi-ingredient
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synergistic formulations [38].We suggest that rationally designed
polyherbal formulations also could be explored as an option
for multitarget therapeutic and prophylactic applications. Both
TCM and Ayurveda, over thousands of years have developed
various practical theories to create polyherbal formulations in
which multiple agents contained in one formula act synergisti-
cally [39].
Development of standardized, synergistic, safe and effective
traditional herbal formulations with robust scientific evidence
can also offer faster and more economical alternatives. For
instance, Ayurvedic texts include thousands of single or polyher-
bal formulations [40]. These have been rationally designed and
have been in therapeutic use for many years. Sufficient pharma-
coepidemiological evidence, based on actual clinical use, can be
generated to support their safety and efficacy [41]. Systematic data
mining of the existing formulations’ huge database can certainly
help the drug discovery processes to identify safe candidates and
synergistic formulations.
The FDA and a few other agencies have come up with practical
guidelines for botanical ‘drug’ development [42]. A botanical
drug product often has unique features andmay include complex
mixtures with as yet unknown active ingredients Some botanical
drugs, including cascara, psyllium and senna, are included in the
over-the-counter drug review. No botanical products are, how-
ever, currently approved or marketed as prescription drugs. The
FDA recognizes that prior human experience with botanical
products may be documented in many different forms and
sources, some of which may not meet the quality standards of
modern scientific testing. The FDA, maintains, however, the
same standards for safety and efficacy for marketing approval
whether it is a botanical-sourced product or a purified chemical.
The Botanical Guidance simply recommends the use of different
types of data for preliminary safety consideration. It also con-
siders large quantities ofmostly anecdotal human data in place of
well-controlled animal studies and human trials in an IND [43].
In such a situation, traditional medicine data remains very
important.
Traditional herbal formulations could follow such regulatory
guidance to create scientific evidence base with robust chemistry,
manufacturing and controls. Department of Ayurveda, Yoga,
Unani, Siddha, Homeopathy (AYUSH) in India has recently estab-
lished a Research Center at the University of Mississippi, Oxford,
MS, USA to facilitate scientific investigations on Indian herbal
drugs. Such efforts should help improve quality assurance, enhan-
cing the chance of regulatory approvals and improving the accep-
tance of botanical drug products and formulations.
Thus, if safe and effective herbal formulations are developed in
accordance with stringent regulatory guidelines on a par with any
modern drug, we hope that the conventional skepticism against
herbals may slowly wane. Issues related to the appropriateness of
conventional biomedical and clinical models for evaluating effi-
cacy of traditional medicine remain, however, very crucial. A
holistic approach based on systems biology seems much more
suited to study therapeutic efficacy and pharmacodynamics of
traditional medicine-based drug development [44]. It can also
be argued that instead of randomized controlled trials, strategies
of pragmatic clinical trials may be better suited for traditional
medicine-inspired reverse pharmacology approaches [45]. We pre-
sent here two case studies where herbal formulations were success-
fully developed using such strategies.
NMITLI scheme
The osteoarthritis herbal drug development project under the
NMITLI scheme involved a network of 16 national research insti-
tutions, modern medicine hospitals and pharmaceutical indus-
tries from India (Fig. 2). Following literature search [46] and several
rounds of national level consultations with Ayurvedic physicians
and scholars, judiciously short-listed botanical drugs entered a
parallel track of animal pharmacology and open label observa-
tional studies by clinicians. The project used a traditional knowl-
edge-guided platform where the base formulation was optimized
with additional ingredients to obtain desired therapeutic activ-
ities. All the formulations were manufactured under Good Man-
ufacturing Practices in accordance using FDA guidance to Industry
for botanical drugs. The preclinical evaluationwas designed on the
basis of a systems approach, wherein the assay battery involved
targets relevant to inflammation, pain, immunomodulation and
chondroprotection in human explant models of OA cartilage
damage [47]. This led to the design a few variants of synergistic
polyherbal formulations that were found to be safe and devoid of
any genotoxicity or mutagenic activity. The short-listed formula-
tions entered a series of randomized clinical trials together with
known drugs, glucosamine and celecoxib, for comparison. Finally
the best formulation was selected that led to one Indian and one
Patent Cooperation Treaty (PCT) applications. A dossier of neces-
sary data required for possible regulatory submissions was also
prepared [48,49]. Thus, this project was completed in five years
with an expenditure of about 2million US dollars. Currently, CSIR
is in the process of identifying a suitable industrial partner for
further development, optimization, manufacturing, registration
and marketing.
Tanga project
In Tanzania, The Tanga AIDS Working Group (TAWG) has used
indigenous knowledge (IK) in an attempt to alleviate suffering
from HIV/AIDS. The group has treated over 4000 AIDS patients
with herbs prescribed by local healers. The impact has been
most significant in reducing opportunistic diseases accompany-
ing HIV infection. The Tanga regional hospital, a modern
medicine facility, has been involved in testing patients for
HIV, treating them and providing counseling. With support
from the World Bank’s Indigenous Knowledge for Development
Program, TAWG has organized community-to-community
exchanges, involving their healers, people living with AIDS
and staff working with patients to provide medical care and
alternative income generating opportunities, in exchange of IK
with other communities in Tanzania [50]. Such experiences are
also important in scientific or rational drug discovery process. A
crucial challenge is to lever local and global knowledge systems
effectively to resolve development challenges. To facilitate this
process, the Global Research Alliance (GRA) and the World Bank
have initiated a partnership between the TAWG and the US
National Institutes of Health to cooperate on the scientific
validation of the efficacy of these herbal treatments. During
the recent launch of the Global Indigenous Knowledge and
Innovation Partnership (GIKIP) in New York, the Tanga project
Drug Discovery Today  Volume 14, Numbers 15/16 August 2009 REVIEWS
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was showcased prominently (http://www.research-alliance.net/
GIKIP_Launched.html).
Future perspectives
Drug discovery and development is an extremely complex, tech-
nology and capital-intensive process that is facing major chal-
lenges with the current target rich–lead poor situation. A major
cause of attrition in drug discovery is due to toxicity in human
trials and it is known that drugs with novel mechanisms have
higher attrition rates. Better validated preclinical targets with
proof-of-concept of better efficacy and safety of drugs can, how-
ever, mitigate such attrition risks. We propose that the reverse
REVIEWS Drug Discovery Today Volume 14, Numbers 15/16 August 2009
FIGURE 2
NMITLI osteoarthritis project: national institutional network, steps and responsibilities.
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pharmacology approach can be useful in this process and help in
reducing failure rates [51].
Seeking new synergistic combinations and improvements in
bioavailability are innovative strategies, that can play a significant
role in drug development. For instance, in animal studies, a
combination of artemisinin derivative and curcumin has been
reported to show a synergistic interaction in killing Plasmodium
falciparum leading effectively to total survival [52]. There have
been several studies on piperine showing its combination
improved bioavailability of synthetic drugs such as propranolol,
theophylline and rifampicin. The clue for piperine as a bioenhan-
cer came from Ayurveda [53]. Such bioavailability enhancing
activity may have numerous advantages in drug development
including reduction in dose, toxicity and treatment costs.
Herbalome is an ambitious project from China that is expected
to undertake high-throughput screening, toxicity testing and
clinical trials to identify active compounds and toxic contami-
nants in popular recipes to identify scores of drug candidates [54].
It is believed that drugs based on traditionalmedicinemay provide
a cost-effective alternative to protein-based or other biotech-based
expensive therapeutics [55]. Multisite mechanisms of action of
herbal preparations from the crude extracts may offer greater
chances for success where conventional single-site agents have
been disappointing.
Single drugs, however, may not be an optimal way to treat a
patient, with so many characteristics that are so individual,
associated, of course with the challenges of genetic diversity.
Genome-wide functional screening against disease targets may
be the practical approach. Combining Ayurveda and functional
genomics in a systems biology scenario may reveal the pathway
analysis of crude andactive components [56]. Pharmacogenomics
is now significantly influencing drug discovery and genotyping is
recommended for drugs that are metabolized by enzymes whose
genes have inactivating polymorphisms [57]. Efforts to correlate
genotype and phenotype-based traditional methodology of clas-
sifying humans into three major Prakriti types or constitutions
described in Ayurveda have opened an exciting scientific chapter
and will help the progress of individualizedmedicine approaches
[58,59].
The issue of protecting intellectual property rights poses special
challenges in such approaches based on natural resources. The
Traditional Knowledge Digital Library (TKDL) developed by CSIR
and AYUSH offer unique technologies (http://www.tkdl.res.in/).
The TKDL has been able to provide a scientific classification
structure to traditional knowledge, resulting in an altogether
new resource classification system. The issues relating to patenting
of new products that rely on old knowledge are also important.
The European Patent Office has been recently given access to the
TKDL database so that patent applications relying on Indian
traditional remedies can be blocked at an early stage. Similar
arrangements with the US Patent Office and others are also under-
way.
Another ambitious project named AyuSoft involves systems
standardization for an integrated, intelligent and communicative
decision support system (http://ayusoft.cdac.in/). AyuSoft has
converted classical Ayurvedic textual knowledge into comprehen-
sive, authentic, intelligent and interactive repositories with com-
plex analytical tools that can be used as a powerful discovery
resource [60]. A systematic medicinal plants database also remains
very crucial and important tool for bioprospecting. NAPRALERT –
a relational database of natural products developed by the Uni-
versity of Illinois at Chicago (http://www.napralert.org/) and the
online Encyclopedia of Indian Medicinal Plants developed by the
Foundation for Revitalisation of Local Health Traditions (FRLHT)
now known as Indian Institute of Ayurveda and Integrative Med-
icine (IIAIM), Bangalore, India (http://www.frlht.org.in/) are two
most available valuable resources.
The World Health Organization’s Commission on Intellectual
Property and Innovation in Public Health has also recognized
the promise and role of traditional medicine in drug develop-
ment for affordable health solutions [61]. Many countries for
example India, China, Korea, Malaysia, Brazil, South Africa,
Australia and the like are becoming increasingly aware of the
value of their traditional knowledge. On the other hand, the
global pharmaceutical industry is looking for innovative solu-
tions to expedite the discovery process. Therefore, innovative
approaches inspired by traditional knowledge like Ayurveda may
aptly occupy this niche strategy to expedite drug discovery and
development process especially in the existing global economic
environment.
Admittedly, despite the vast potential and possibilities, as of
now, very few success stories have emerged from Ayurveda. This
may be because most of the work in this field has remained within
the clinics of traditional practitioners or confined to academic
research laboratories and not taken seriously by industries that are
strong in research and development. Therefore, path-breaking
initiatives like NMITLI in India are crucially important. The Gov-
ernment of India’s golden triangle project integrating biomedi-
cine, modern sciences and traditional medicine is indicative of a
trend where traditional sciences like Ayurveda are increasingly
embracing the scientific evidence-base and the spirit of robust
research [62].
Finally, after this discussion of traditional medicine-inspired
approaches to drug discovery, we return to the question posed in
the title: Can Ayurveda show the way forward? We can offer an
assertive answer, albeit with caveats. Great traditions like Ayur-
veda and TCM certainly offer sound rationale, valuable experien-
tial wisdom and a large database of botanical resources. For several
reasons, researchers involved in the modern drug discovery have
started revisiting ancient traditional knowledge and ethnophar-
macology, especially to develop new, effective synergistic drug
combinations for management of difficult to treat conditions like
cancer and dementia. Many promising leads like curcumins, with-
anoloides and the like offer a great hope, and need to be taken to
their logical conclusions. A paradigm shift in innovation strategy
is needed, involving, among other things, revisiting the vast
possibilities that the Ayurveda and other global traditional knowl-
edge bases offer. A strong conduit between Ayurveda, academia
and industry coupled with robust evidence-based research and
mutually respected public private partnership is possibly the right
way forward.
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